BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person ImmuneBD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune

BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry

2025/12/18 20:15
4 min di lettura
Per feedback o dubbi su questo contenuto, contattateci all'indirizzo [email protected].

BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study

FRANKLIN LAKES, N.J., Dec. 18, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania, to advance research in deep human immune profiling and support the development of immune-mediated therapies.

The collaboration includes developing and validating a high-parameter flow cytometry panel that can capture key functional pathways in whole blood, including phosphorylation markers, which provide powerful insight into how single cells respond to drugs or disease states. The panel will support a planned 1,000-patient immune profiling study, in partnership with the Penn Colton Center for Autoimmunity, expected to start this summer. The project will leverage the BD FACSDiscover™ A8 Cell Analyzer, BD Rhapsody™ System, BD reagents, software and informatics, with BD teams managing reagents, instrumentation, and spectral data algorithms, and I3H teams serving as scientific and clinical leads. The team intends to publish a peer-reviewed manuscript describing the results of the study.

“This project demonstrates the power of collaboration between academia and industry,” said Dr. E. John Wherry, PhD, the Richard and Barbara Schiffrin President’s Distinguished Professor, director of the Institute for Immunology and Immune Health at the University of Pennsylvania, and the director of the Colton Consortium for Autoimmunity. “We are bringing together cross-functional experts to transform human immune profiling for maximum impact, enabling deeper insights from our immune cells that could accelerate development of precise medical treatments.”

The collaboration reflects a shared vision of unlocking the power of the human immune system to advance science and health. It is made possible by the BD FACSDiscover™ A8 Cell Analyzer, which is the first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, and the new BD Horizon™ Chroma solution for dried high-parameter panels. The project supports the commitment of both organizations to contribute to the research community through collaboration and knowledge sharing.

“High-parameter single-cell studies of this kind, once considered infeasible, are increasingly becoming central to better understanding the human immune system,” said Steve Conly, worldwide president of BD Biosciences. “Our ecosystem of industry-leading BD flow cytometers, single-cell systems, reagents, software and informatics, provide a critical missing puzzle piece that can support the important work of organizations like I3H to translate and deliver immunological insights into quantitative, actionable information for discovery and clinical care teams around the world.”

More information is available at bdbiosciences.com.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Contacts:

Media:

Investors:

Fallon McLoughlin

Adam Reiffe

Director, Public Relations

VP, Investor Relations

201.258.0361

201.847.6927

[email protected]

[email protected]

Media for Penn Medicine:

Eric Horvath

Associate News Director

Penn Medicine

215-821-4289

[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-and-penn-institute-for-immunology-and-immune-health-collaborate-to-advance-immunotherapy-through-flow-cytometry-302645260.html

SOURCE BD (Becton, Dickinson and Company)

Opportunità di mercato
Logo FLOW
Valore FLOW (FLOW)
$0.04678
$0.04678$0.04678
+14.29%
USD
Grafico dei prezzi in tempo reale di FLOW (FLOW)
Disclaimer: gli articoli ripubblicati su questo sito provengono da piattaforme pubbliche e sono forniti esclusivamente a scopo informativo. Non riflettono necessariamente le opinioni di MEXC. Tutti i diritti rimangono agli autori originali. Se ritieni che un contenuto violi i diritti di terze parti, contatta [email protected] per la rimozione. MEXC non fornisce alcuna garanzia in merito all'accuratezza, completezza o tempestività del contenuto e non è responsabile per eventuali azioni intraprese sulla base delle informazioni fornite. Il contenuto non costituisce consulenza finanziaria, legale o professionale di altro tipo, né deve essere considerato una raccomandazione o un'approvazione da parte di MEXC.

Potrebbe anche piacerti

Litecoin Fluctuates Below The $116 Threshold

Litecoin Fluctuates Below The $116 Threshold

The post Litecoin Fluctuates Below The $116 Threshold appeared on BitcoinEthereumNews.com. Sep 17, 2025 at 23:05 // Price Litecoin price analysis by Coinidol.com: LTC price has slipped below the moving average lines after hitting resistance at $120. Litecoin price long-term prediction: bearish The 21-day SMA support helped to alleviate the selling pressure. In other words, the price of the cryptocurrency is above the 21-day SMA support but below the 50-day SMA barrier. This suggests that Litecoin will be trapped in a narrow range for a few days. If the 21-day SMA support or the 50-day SMA barrier is overreached, the cryptocurrency will trend upwards. For example, if the LTC price breaks through the 50-day SMA barrier, it will rise to a high of $124. Litecoin will fall to its current support level of $106 if the 21-day SMA support is broken. Technical Indicators  Resistance Levels: $100, $120, $140 Support Levels: $60, $40, $20 LTC price indicators analysis Litecoin’s price is squeezed between the moving average lines. It is unclear in which direction Litecoin will move. The moving average lines are horizontal in both charts. However, the price bars are limited to the distance between the moving averages. The price bars on the 4-hour chart are below the moving average lines. LTC/USD price chart – September 17, 2025 What is the next move for LTC? On the 4-hour chart, Litecoin is currently trading in a bearish trend zone. The altcoin is trading above the $112 support and below the moving average lines, which represent resistance at $116. The upward movement is hindered by the moving average lines, which are causing the price to oscillate within a limited range. Meanwhile, the signal for the cryptocurrency is bearish, with price bars below the moving average…
Condividi
BitcoinEthereumNews2025/09/18 08:15
XRP Price Watch: Price Action Tightens in Micro Range as Bulls Seek Control

XRP Price Watch: Price Action Tightens in Micro Range as Bulls Seek Control

The post XRP Price Watch: Price Action Tightens in Micro Range as Bulls Seek Control appeared on BitcoinEthereumNews.com. On Sunday, XRP is trading at $2.99 with a market capitalization of $178 billion and a 24-hour trading volume of $3.34 billion. The intraday price range sits narrowly between $2.97 and $3.01, suggesting a temporary equilibrium between buyers and sellers. XRP The 1-hour chart reflects a period of choppy, range-bound trading, typical of market indecision. […] Source: https://news.bitcoin.com/xrp-price-watch-price-action-tightens-in-micro-range-as-bulls-seek-control/
Condividi
BitcoinEthereumNews2025/09/21 22:41
River Token Plunges 20.8% in 24 Hours: On-Chain Data Reveals Pressure Points

River Token Plunges 20.8% in 24 Hours: On-Chain Data Reveals Pressure Points

River (RIVER) experienced a sharp 20.8% decline to $12.35 within 24 hours, erasing $64 million in market capitalization. Our data analysis reveals concerning volume
Condividi
Blockchainmagazine2026/03/09 18:04